 |
|
Hope remains for Alzheimer's sufferers
October 31, 2006The National Institute of Clinical Excellence (NICE), who last week rejected appeals to allow patients with mild Alzheimer's to receive the life-changing medication donepezil (Aricept®), will hopefully re-appraise their decision in three-years time, according to neurologist Professor Robert Kerwin in an article published in the November issue of the medical journal Future Neurology.
Kerwin evaluated recent research published in the Lancet that may not have been taken into account by the NICE committee. In this study, nursing home patients with severe Alzheimer's disease were administered with donepezil, or a placebo drug, and were observed for 6-months. Those patients receiving donepezil treatment showed significantly improved cognitive function, compared with those patients not receiving the drug, despite recommendations by NICE not to prescribe donepezil to this patient group.
Kerwin also evaluates recent data suggesting that the drugs are effective in patients with milder forms of Alzheimer's disease. The recent 2005 NICE revised guidelines for cholinesterase inhibitors, the class of drug that donepezil and other Alzheimer drugs rivastigmine(Exelon®/Prometax®) and galantamine (Reminyl®) belong to, state that these drugs can only be administered to patients with moderate Alzheimer's, for whom NICE believe the evidence is strongest. At the same time NICE withdrew its recommendations for the use of these drugs for patients with mild-to-moderate Alzheimer's. Memantime (Exiba®), belonging to another class of drugs, is not recommended to Alzheimer's sufferers, but is restricted to ongoing clinical trials and may be possible treatment in the future.
"NICE's decisions are based upon the economic health calculations that they do, which are balanced against clinical benefit. Even though the drugs do work in the long-term, patients do progress to requirements of alternative care that do not necessarily lead to savings within the NHS." Commented Kerwin, who is a Professor of Clinical Neuropharmacology at the Institute of Psychiatry, London.
750,000 people are estimated to suffer from Alzheimer's disease in the UK alone, with 78,000 of these receiving rivastigmine, galantamine and memantine; a further 2-thirds of sufferers take donepezil. Since NICE's original 2001 guidelines that this family of drugs should be made broadly available within the UK NHS for mild-to-moderate Alzheimer's disease, prescriptions have risen sharply and many sufferers have experienced a welcome relief from the debilitating symptoms of memory loss and cognitive decline. In 2005, NICE reviewed their previous decision based on the cost effectiveness and clinical benefit of such drugs in mild- and severe-Alzheimer's sufferers, and ruled that the drugs should be limited only to patients with moderate forms of the disease. This is only applicable to newly diagnosed patients. Despite uproar from patient groups appealing this decision, NICE stuck by their guidelines and last week issued a statement over-ruling the appeal.
"It is a bizarre decision," continued Kerwin, "the economists in the appraisal may well have had sway over the clinicians in the appraisal, and the clinicians may, on the other hand, have said that the drugs do help mild patients to quite a significant degree. I personally think NICE would have made a mistake over this decision if it is dominated by health economists rather than clinicians, however I have no knowledge of the final deliberations of the NICE committee." Kerwin, who once sat on the NICE committee appraising these drugs, points out that they would only have analysed current data in their review and that more recent data, published in the gap between the final draft of the appraisal and the appeal, would possibly not have been taken into account. NICE would only have evaluated their process and the methods used to reach such a decision.
"These drugs work in ways that are not predictable for severe Alzheimer's disease patients, which suggests there is an added mechanism. Mild patients will always do better, everybody knows that, but the economic sums don't quite fully add up in terms of cost. I believe that progression, when measured economically rather than clinically, may not be very impressive."
Despite the recent uproar, Kerwin remains hopeful that with new data, such as those analysed in his article on severe Alzheimer's disease patients, NICE could potentially reverse their decision due to their working principal of 'positive review' on a 3-yearly cycle. Future Neurology is published by Future Medicine an imprint of the Future Science Group.
Future Science Group
"NICE's decisions are based upon the economic health calculations that they do, which are balanced against clinical benefit. Even though the drugs do work in the long-term, patients do progress to requirements of alternative care that do not necessarily lead to savings within the NHS." Commented Kerwin, who is a Professor of Clinical Neuropharmacology at the Institute of Psychiatry, London.
750,000 people are estimated to suffer from Alzheimer's disease in the UK alone, with 78,000 of these receiving rivastigmine, galantamine and memantine; a further 2-thirds of sufferers take donepezil. Since NICE's original 2001 guidelines that this family of drugs should be made broadly available within the UK NHS for mild-to-moderate Alzheimer's disease, prescriptions have risen sharply and many sufferers have experienced a welcome relief from the debilitating symptoms of memory loss and cognitive decline. In 2005, NICE reviewed their previous decision based on the cost effectiveness and clinical benefit of such drugs in mild- and severe-Alzheimer's sufferers, and ruled that the drugs should be limited only to patients with moderate forms of the disease. This is only applicable to newly diagnosed patients. Despite uproar from patient groups appealing this decision, NICE stuck by their guidelines and last week issued a statement over-ruling the appeal.
"It is a bizarre decision," continued Kerwin, "the economists in the appraisal may well have had sway over the clinicians in the appraisal, and the clinicians may, on the other hand, have said that the drugs do help mild patients to quite a significant degree. I personally think NICE would have made a mistake over this decision if it is dominated by health economists rather than clinicians, however I have no knowledge of the final deliberations of the NICE committee." Kerwin, who once sat on the NICE committee appraising these drugs, points out that they would only have analysed current data in their review and that more recent data, published in the gap between the final draft of the appraisal and the appeal, would possibly not have been taken into account. NICE would only have evaluated their process and the methods used to reach such a decision.
"These drugs work in ways that are not predictable for severe Alzheimer's disease patients, which suggests there is an added mechanism. Mild patients will always do better, everybody knows that, but the economic sums don't quite fully add up in terms of cost. I believe that progression, when measured economically rather than clinically, may not be very impressive."
Despite the recent uproar, Kerwin remains hopeful that with new data, such as those analysed in his article on severe Alzheimer's disease patients, NICE could potentially reverse their decision due to their working principal of 'positive review' on a 3-yearly cycle. Future Neurology is published by Future Medicine an imprint of the Future Science Group.
Future Science Group
Alzheimers Current Events and Alzheimers News RSSPreimplantation genetic diagnosis may pose neurological risks
Preimplantation genetic diagnosis (PGD) has helped many couples conceive healthy children and is generally considered a safe practice.
New studies give clear guidance on how to better recruit volunteers for Alzheimer's clinical studies
Partnering with local physicians, working with local clinics, and conducting educational seminars and health fairs were found to be the most effective tools in recruiting people for Alzheimer's clinical studies.
A Penny for Your Prions
North Carolina State University researchers have discovered a link between copper and the normal functioning of prion proteins, which are associated with transmissible spongiform encephalopathy diseases such as Cruetzfeldt-Jakob in humans or "mad cow" disease in cattle.
Structural polymorphism of 441-residue Tau at single residue resolution
Worldwide almost 30 million suffer from Alzheimer's disease, an irreversible, neurodegenerative condition that is eventually fatal.
Families shed light on likely causative gene for Alzheimer's
The genetic profile of two large Georgia families with high rates of late-onset Alzheimer's disease points to a gene that may cause the disease, researchers say.
Scientists explore consciousness
An international team of scientists led by a University of Leicester researcher has carried out a scientific study into the realm of consciousness.
High-Trauma Fractures in Older Men and Women Linked to Osteoporosis
Researchers at the California Pacific Medical Center (CPMC) Research Institute are challenging a widely held belief that fractures resulting from major trauma, such as automobile accidents, are not related to osteoporosis, the common disease that makes bones weak and prone to fracture.
What makes Mars magnetic?
Earth's surface is a very active place; its plates are forever jiggling around, rearranging themselves into new configurations. Continents collide and mountains arise, oceans slide beneath continents and volcanoes spew.
Cold sore virus might play role in Alzheimer's disease
A gene known to be a major risk factor for Alzheimer's disease puts out the welcome mat for the virus that causes cold sores, allowing the virus to be more active in the brain compared to other forms of the gene.
Study offers window into human behavior, brain disease
UCSF scientists have identified a cell population that is a primary target of the degenerative brain disease known as frontotemporal dementia, which is as common as Alzheimer's disease in patients who develop dementia before age 65.
More Alzheimers Current Events and Alzheimers News Articles
 |
Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease by Joanne Koenig Coste (Author), Robert Butler (Foreword) More than four million Americans suffer from Alzheimer’s, and as many as twenty million have close relatives or friends with the disease. Revolutionizing the way we perceive and live with Alzheimer’s, Joanne Koenig Coste offers a practical approach to the emotional well-being of both patients and caregivers that emphasizes relating to patients in their own reality. Her accessible and comprehensive method, which she calls habilitation, works to enhance communication between carepartners and patients and has proven successful with thousands of people living with dementia. Learning to Speak Alzheimer’s also offers hundreds of practical tips, including how to · cope with the diagnosis and adjust to the disease’s progression · help the patient talk about the illness · face the... |
 |
A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier by Patricia R. Callone (Editor) Written for patients, their families, and caregivers, the practical information here will help readers understand what is physically happening to the brain so they can empower their own special skills and talents throughout the disease process. The book is divided into three sections that correspond to the progression of Alzheimer’s, and the unique challenges encountered at each stage. *Section A: The four stages of Alzheimer's with hundreds of practical tips for coping at each level *Section B: Q&A for caregivers, including legal and financial issues, medication, helping children understand, handling the holidays and more. *Section C: Resources and websites. This is an essential book for all those who want to focus on the capabilities that... |
 |
The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease, Other Dementias, and Memory Loss in Later Life, 4th Edition by Nancy L. Mace (Author), Peter V. Rabins (Author) Revised in 2006 for its twenty-fifth anniversary, this best-selling book is the "bible" for families caring for people with Alzheimer disease, offering comfort and support to millions worldwide. In addition to the practical and compassionate guidance that have made The 36-Hour Day invaluable to caregivers, the fourth edition is the only edition currently available that includes new information on medical research and the delivery of care. The new edition includes: -new information on diagnostic evaluation-resources for families and adult children who care for people with dementia-updated legal and financial information-the latest information on nursing homes and other communal living arrangements-new information on research, medications, and the biological causes and... |
 |
The Alzheimer's Project Starring: Maria Shriver Alzheimer’s is the second-most-feared illness in America following cancer, and it is the nation’s sixth leading cause of death. Is such anxiety justified? The answer, until recently, was not comforting. The Alzheimer’s Project consists of 4 films. The anchor of The Alzheimer’s Project series is Momentum in Science which features 25 leading scientists, a primetime state-of-the-science report revealing the most cutting-edge research advances. The three additional primetime specials (The Memory Lost Tapes; Grandpa, Will You Remember Me? With Maria Shriver; and Caregivers) capture what it means to experience the disease, to be a child or grandchild of one who suffers, and to care for those who are affected. Alzheimer’s is an irreversible and progressive brain disease that slowly... |
 |
Alzheimer's from the Inside Out by Richard Taylor (Author) Receiving a diagnosis of Alzheimer’s disease profoundly alters lives and creates endless uncertainty about the future. How does a person cope with such a life-changing discovery? What are the hopes and fears of someone living with this disease? How does he want to be treated? How does he feel as the disease alters his brain, his relationships, and ultimately himself?
Richard Taylor provides illuminating responses to these and many other questions in this collection of provocative essays. Diagnosed with Alzheimer’s disease at age 61, the former psychologist courageously shares an account of his slow transformation and deterioration and the growing division between his world and the world of others.
With poignant clarity, candor, and even occasional humor, more than... |
 |
Still Alice by Lisa Genova (Author) Still Alice is a compelling debut novel about a 50-year-old woman's sudden descent into early onset Alzheimer's disease, written by first-time author Lisa Genova, who holds a Ph. D in neuroscience from Harvard University. Alice Howland, happily married with three grown children and a house on the Cape, is a celebrated Harvard professor at the height of her career when she notices a forgetfulness creeping into her life. As confusion starts to cloud her thinking and her memory begins to fail her, she receives a devastating diagnosis: early onset Alzheimer's disease. Fiercely independent, Alice struggles to maintain her lifestyle and live in the moment, even as her sense of self is being stripped away. In turns heartbreaking, inspiring and terrifying, Still Alice captures in remarkable... |
 |
Inside Alzheimer's: How to Hear and Honor Connections with a Person who has Dementia by Nancy Pearce (Author) We have long underestimated the person who has dementia. Each one's ability to reach out in familiar ways certainly diminishes yet he or she is always able to experience the deep benefits that come from being in vital relationship with others. Inside Alzheimer's tells how dozens of persons with dementia and their sharing of wisdom, humor and life's teachings led Ms. Pearce to the six basic principles of connection--how one person connects with another: Intend a connection, Free yourself of judgment, Love, Open to receive love, Silence and Thankfulness. Internalizing these principles has empowered hundreds of family, friends, and professionals to create moments of connection with persons, regardless of how advanced the dementia. |
 |
Alzheimer's Early Stages: First Steps for Family, Friends and Caregivers by Daniel Kuhn (Author), M.D. David A. Bennett (Foreword) This edition includes the latest information on Alzheimer’s risk factors, treatments, and prevention, as well as a new chapter, "Voices of Experience," composed of reflections by family members. It also provides information about new drugs approved since 1999 and the federal government’s decision to cover counseling and other health-related services through Medicare. |
 |
The Anti-Alzheimer's Prescription: The Science-Proven Prevention Plan to Start at Any Age by Vincent Fortanasce (Author) From a world-renowned neurologist, the first book to feature a scientifically substantiated program for the only treatment for Alzheimer's: PREVENTION Alzheimer's is a devastating and frightening disease, and as baby boomers age it's on the brink of becoming the great epidemic of the twenty-first century. Fortunately, by making proper lifestyle choices and avoiding certain risk factors, most people can prevent Alzheimer's, and it can be delayed in those who are genetically predisposed. The Anti- Alzheimer's Prescription presents a unique four-step program that includes menus, recipes, exercises, stress reduction techniques, and neurobics to lower the risk of Alzheimer's by as much as 70 percent. Dr. Fortanasce, who witnessed his own father's painful decline from the... |
 |
Alzheimer's Disease: Facing the Facts Starring: n/a Directed By: n/a Studio: Wgbh Wholesale Release Date: 03/17/2009 Run time: 56 minutes |
| © 2009 BrightSurf.com |